POEMS syndrome: 2017 Update on diagnosis, risk stratification, and management

Medicine & Life Sciences

• POEMS Syndrome 100%
• Risk Management 70%
• Plasma Cells 55%
• Polyradiculoneuropathy 28%
• Castleman Disease 25%
• Peripheral Nervous System Diseases 19%
• Vascular Endothelial Growth Factor A 15%
• Plasma Cell Neoplasms 14%
• Clone Cells 14%
• Bone Marrow 13%
• Chronic Inflammatory Demyelinating Polyradiculoneuropathy 12%
• Radiotherapy 12%
• Lenalidomide 12%
• Paraneoplastic Syndromes 12%
• Thrombocytosis 12%
• Papilledema 11%
• Plasmacytoma 11%
• Thalidomide 11%
• Bortezomib 11%
• Alkylating Agents 10%
• Ilium 10%
• Therapeutics 10%
• Delayed Diagnosis 10%
• Stem Cell Transplantation 9%
• Nervous System Diseases 8%
• Anti-Idiotypic Antibodies 7%
• Adrenal Cortex Hormones 7%
• Disease Progression 7%
• Biopsy 5%
• Phenotype 5%
• Bone and Bones 5%
• Skin 5%